SB1317 hydrochloride (1204918-72-8(free base)) NEW
| Price | $115 | $189 | $340 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-12 |
Product Details
| Product Name: SB1317 hydrochloride (1204918-72-8(free base)) | Purity: 99.84% |
| Supply Ability: 10g | Release date: 2025/05/12 |
Product Introduction
Bioactivity
| Name | SB1317 hydrochloride (1204918-72-8(free base)) |
| Description | SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM). |
| In vitro | SB1317 (25 μM) has no inhibition of Human CYP1A2, 3A4, 2C9, and 2C19 isoforms, but has inhibition of CYP2D6 (IC50: 0.95 μM). SB1317 inhibits cell proliferation of HCT-116 (IC50: 0.079 μM) and HL-60 (IC50: 0.059 μM)[1]. SB1317 is mainly metabolized by CYP3A4 and CY1A2 in vitro. SB1317 does not inhibit any of the major human CYPs in vitro except CYP2D6 (IC50=1 μM). CYP1A and CYP3A4 are mainly expressed in human hepatocytes in vitro. |
| In vivo | SB1317 (75 mg/kg/day, p.o., 3×/week) markedly inhibits the growth of tumors with a mean TGI of 82%, while the lower dose (50 mg/kg/day, p.o., 3×/week) is marginally effective. Treatment with SB1317 using either regime significantly inhibits the growth of tumors with mean TGIs of 42% (p.o.) and 63% (i.p.), respectively[1]. In pharmacokinetic studies, SB1317 shows moderate to high systemic clearance (relative to liver blood flow), high volume of distribution (>0.6 L/kg), oral bioavailability of 24%, ~4 and 37% in mice, rats, and dogs, respectively; and extensive tissue distribution in mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (146.73 mM), Sonication is recommended. |
| Keywords | TG-02 Hydrochloride | TG02 Hydrochloride | TG 02 Hydrochloride | SB1317 hydrochloride (1204918-72-8(free base)) | SB-1317 hydrochloride (1204918-72-8(free base)) | SB1317 hydrochloride (1204918728(free base)) | SB1317 hydrochloride (1204918 72 8(free base)) | JAK2 | FLT3 | CDK2 |
| Inhibitors Related | Ribociclib | Gilteritinib | Nintedanib | Sorafenib | Tofacitinib Citrate | Abemaciclib | Pexidartinib | Sorafenib tosylate | Ruxolitinib phosphate | CASIN | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $133.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-05-20 | |
| $0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 | |
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY